ClinicalTrials.gg
Enrolling by invitationNCT07438639Updated Feb 27, 2026

Virtual Reality-supported Language Intervention for Preschool Children With DLD

An interventional study of Virtual Reality Rehabilitation System (VRRS) and Taditional Speech Therapy in Language Development Disorders, sponsored by IRCCS Centro Neurolesi Bonino Pulejo. Enrolling by invitation at 1 site in Italy. Open to participants aged 3 Years to 8 Years. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by IRCCS Centro Neurolesi Bonino Pulejo · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years after the study started (first participant enrolled Feb 2023, registered Feb 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
3 Years to 8 Years
Sex
All
01

Study summary

This study aims to test the effectiveness of virtual reality-supported speech therapy in improving basic language skills in children aged 3 to 6 years diagnosed with Developmental Language Disorder (DLD). Participants are randomly assigned to either traditional speech therapy or virtual reality-supported therapy, with the same frequency and duration of intervention. Language outcomes are assessed before and after treatment using the Language development level test (TVL), a standardized assessment of Italian for preschoolers. The study adopts a randomized controlled design with individualized, goal-oriented therapy delivered by certified speech-language pathologists.

02

Conditions studied

  • Language Development Disorders
03

In context

Language Development Disorders

121 studies on the registry are indexed under Language Development Disorders; 49 are open to participants now.

This study's planned enrollment of 100 is above the median of 74 across 106 interventional studies indexed under Language Development Disorders.

Browse Language Development Disorders studies →

Lead sponsor

IRCCS Centro Neurolesi Bonino Pulejo is the lead sponsor of 67 studies on the registry; 31 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 8 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 3 and 6 years at enrollment
  • Clinical diagnosis of Developmental Language Disorder (DLD) based on and standardized language assessments
  • Developmental Quotient (DQ) > 70 on the Griffiths III Scales
  • Good general health without neurological or psychiatric comorbidities
  • signed by a parent or legal guardian

Exclusion criteria

Exclusion Criteria:

  • Age not between 3 and 6 years
  • Lack of clinical diagnosis of Developmental Language Disorder (DLD)
  • Developmental Quotient (DQ) \< 70 on the Griffiths Scale III
  • Presence of neurological or psychiatric comorbidities
  • Lack of signed from a parent or legal guardian
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    VR-Supported Speech Therapy

    Children receive two 60-minute sessions per week for six months using the Virtual Reality Rehabilitation System (VRRS).

    Device: Virtual Reality Rehabilitation System (VRRS)

  • Active comparator
    Traditional Speech Therapy

    Children receive the same therapy schedule and goals through conventional speech-language sessions using printed materials, games, and verbal interaction.

    Behavioral: Taditional Speech Therapy

Interventions

  • DeviceVirtual Reality Rehabilitation System (VRRS)

    The VRRS delivers personalized language therapy exercises via touchscreen interface. Activities target receptive language, repetition, naming, and spontaneous language production. All sessions are conducted by trained speech-language pathologists in accordance with standardized therapeutic protocols.

  • BehavioralTaditional Speech Therapy

    Standard speech-language therapy delivered in-person by certified therapists, targeting the same language domains with paper-based and interactive materials.

06

What researchers measure

Primary outcomes

  1. Language Development Level Test (TVL)

    The Test of Verbalization and Language Development is a standardized tool designed to assess various aspects of language development, including verbal production, comprehension, sentence construction, phonological accuracy, and morphosyntactic abilities. The weighted score ranges from 0 to 10, with higher scores indicating better language development.

    Time frame: Baseline and Month 3

Secondary outcomes

  1. Griffiths III Scales

    General cognitive development will be assessed using the Griffiths III Scales of Child Development. The Global Developmental Quotient, DQ, has a possible range from 50 to 150, with higher scores indicating better developmental and cognitive functioning. The DQ will be used as an index of overall cognitive functioning and as a potential moderator in the analysis of language outcomes.

    Time frame: Baseline

07

Study locations

1 site
08

References and documents

Publications

  • Cappadona I, Ielo A, La Fauci M, Tresoldi M, Settimo C, De Cola MC, Muratore R, De Domenico C, Di Cara M, Corallo F, Tripodi E, Impallomeni C, Quartarone A, Cucinotta F. Feasibility and Effectiveness of Speech Intervention Implemented with a Virtual Reality System in Children with Developmental Language Disorders: A Pilot Randomized Control Trial. Children (Basel). 2023 Aug 1;10(8):1336. doi: 10.3390/children10081336. PubMed 37628335 ↗
  • van Vuuren S, Cherney LR. A Virtual Therapist for Speech and Language Therapy. Intell Virtual Agents. 2014 Jan 1;8637:438-448. doi: 10.1007/978-3-319-09767-1_55. PubMed 25938137 ↗
  • De Domenico C, La Fauci M, Mancuso N, Caputo M, Di Cara M, Piccolo A, Fulgenzi A, Borzelli D, Impallomeni C, Tripodi E, Calabro RS, Quartarone A, Cucinotta F. Virtual Reality-Supported Speech Therapy in Children with Developmental Language Disorder: A Randomized Controlled Trial. Med Sci (Basel). 2026 Jun 5;14(2):291. doi: 10.3390/medsci14020291. PubMed 42346830 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Nov 2026, 45 months after the start.

Of 72 non-industry interventional studies with no phase under Language Development Disorders, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 57. This study's planned 45 months is above that.

Counting every sponsor, half of 72 studies reached it within 30 months; a quarter within 19 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2026
First posted
Feb 27, 2026
StartActual
Feb 1, 2023
Primary completionEst.
Nov 2026
CompletionEst.
Dec 2026
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07438639
Lead sponsor
IRCCS Centro Neurolesi Bonino Pulejo
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Feb 1, 2023
Primary completion
Nov 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Feb 27, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion